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Tardiovascular Prevention in
symptomatic Diabetic Patients
he recent paper by Diamond et al. (1) comparing costs and
ffectiveness of using myocardial perfusion scintigraphy (MPS) as
screening strategy against an unconditional treatment strategy for
he prevention of cardiovascular events in asymptomatic diabetic
atients using a “back of the envelope” calculation contains fatal
rrors. Table 1 of their article, page 1916, detailing the cost
nalysis to the end of year 1, front-loads the entire MPS testing
ost ($11.3 billion) into the first year of this multi-year program,
hen in fact, the benefit from testing accrues into year 2 and
eyond without the cost. Instead of looking at the result at the end
f year 1, Diamond et al. (1) should have looked at the costs under
teady-state conditions. At steady state the number of tests
eeded each year is equal to the number of new individuals
ntering the risk pool plus the number of retests needed on the
est-negative population. According to the National Diabetes
nformation Clearinghouse, a service of the National Institute of
iabetes and Digestive and Kidney Diseases, National Institutes
f Health (2), the prevalence of diabetes in the U.S. in 2005 was
0.8 million, with 14.6 million diagnosed cases, 6.2 million
ndiagnosed cases, and 1.5 million new cases being diagnosed in
ndividuals 20 years and older each year. According to Diamond et
l. (1), there are 11.2 million individuals with a negative test.
lthough no one has ever proposed retesting all the test-negative
ndividuals on an annual basis, just what interval to use for
etesting is not clear from the “Global Dialogue Group for
valuation of Cardiovascular Risk in Patients with Diabetes” (3),
hich advocates for retesting individuals with mild stress perfusion
efects every 2 years, whereas those with normal perfusion scans
ndergo “conventional” follow-up. Giri et al. (4) compared the
urvival curves of 929 diabetic individuals and 3,825 nondiabetic
ndividuals with a normal single-photon emission computed to-
ography (SPECT) study followed for a mean of 2.5  1.5 years
nd found that survival was comparable for the first 2 years;
hereafter, diabetic patients exhibited a sharp increase in cardio-
ascular events. Based on this observation, Hachamovitch et al. (5)
roposed that the “warranty period” of a normal SPECT scan in
iabetics be limited to 2 years. For the purposes of this discussion,
et us assume that all test-negative individuals are retested at 2-year
ntervals. The number of annual retests needed is then 0.5  11.2
5.6 million tests. At steady state, because everyone has been tested
nce, the numbers of individuals treated and events expected and
revented will be the same as the projections by Diamond et al. (1) for
he end of year 1. These numbers are shown in Table 1.
The marginal cost-effectiveness of the unconditional versus the
est-and-treat strategy for cardiovascular event prevention in
symptomatic diabetic patients according to the measures recom-
ended by the Institute of Medicine (6) then is $142,857 gross
ost per additional event prevented, or $10,989 gross cost per
dditional life-year saved. Increasing the interval between retests inhe test-and-treat strategy also would significantly lower the cost of
his program. The gross costs of these programs become identical
hen the price of statins drops 30%, from $2.00/pill to $1.41/pill,
ut the cost-effectiveness becomes equivalent at $1.88/pill because
ore events are prevented by the unconditional treatment strategy.
hese calculations show that although both programs are very
xpensive, the test-and-treat strategy is currently the more cost-
ffective, reversing the conclusions by Diamond et al. (1).
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nconditional Versus Conditional Strategies forardiovascular Event Prevention in Diabetic Patientsder S eady-Stat Conditions
Table 1
Unconditional Versus Conditional Strategies for
Cardiovascular Event Prevention in Diabetic Patients
Under Steady-State Conditions
Treat All Test ¡ Treat
Target population (million) 14 14
New test population (million) 0 1.5
Retest population (million) 0 5.6
TC (million) 14 2.8
Expected events in TC 280,000 224,000
Prevented events in TC 84,000 67,200
Test cost (billion) 0 $5.7
Medication cost (billion) $10.1 $2
Gross cost (billion) $10.1 $7.7
Cost per prevented event $120,238 $106,944
Cost per life-year saved $9,249 $8,226
C  treatment candidates.Regulation. Valuing Health for Regulatory Cost-Effectiveness Analysis.
Washington, DC: National Academies Press, 2006.
